In vitro versus terminal in vivo virulence factor expression.

Data represents the mean and standard deviation of the analyzed biological replicates (three replicates for in vitro; 10 Bcbva CA and 14 Bcbva CI replicates each for in vivo) for hyaluronic acid (A), protective antigen (B), and PDGA capsule (C&...

Full description

Saved in:

Bibliographic Details
Main Author:	Allison M. Ferris (21011700) (author)
Other Authors:	David G. Dawson (21011703) (author), Andrea B. Eyler (21011706) (author), John J. Yeager (21011709) (author), Jordan K. Bohannon (5999951) (author), Jeremy A. Boydston (11320726) (author), Melissa L. Krause (21011712) (author), Charles L. Balzli (21011715) (author), Victoria Wahl (11320771) (author), Tammy D. Jenkins (21011718) (author), Sherry L. Rippeon (21011721) (author), James E. Miller (147575) (author), Susan E. Miller (21011724) (author), David W. Clarke (21011727) (author), Emmanuel Manan (11320747) (author), Ashley F. Harman (21011730) (author), Kim R. Rhodes (21011733) (author), Tina M. Sweeney (21011736) (author), Heather D. Cronin (21011739) (author), Ron L. Bowman (21011742) (author), Michael P. Winpigler (21011745) (author), Heather A. Zimmerman (21011748) (author), Alec S. Hail (11320768) (author), Angelo Scorpio (2113660) (author)
Published:	2025
Subjects:	Biochemistry Medicine Microbiology Genetics Molecular Biology Immunology Infectious Diseases Virology Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified virulence factors harbored virulence factor production new zealand white anthrax vaccine adsorbed quantifying temperature responses evaluate disease course currently available countermeasures disease anthrax due ci ), using bacillus cereus </ bacillus anthracis </ causes inhalational anthrax anthrax mcm efficacies without ava vaccination like disease caused cereus </ anthracis </ like disease pneumonic disease medical countermeasures exposure vaccination disease progression body temperature like plasmids zoonotic organism spores results significant increase progresses quickly possess pxo1 plasmids pxo1 often results medical countermeasure mean time exposure prophylaxis dose dependent data suggest &# 8217
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

<i>In vitro</i> versus terminal <i>in vivo</i> virulence factor expression.

Similar Items